Verteporfin, an FDA-approved photosensitizer, that has been clinically used for the treatment of age-related macular degeneration, was recently found to suppress VM in pancreatic ductal adenocarcinoma by inhibiting MMP-2, VE-cadherin, and a-SMA expression 128. Here, MMP2 is linked to pancreatic ductal adenocarcinoma.